Short Interest in CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) Expands By 25.2%

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) was the target of a significant increase in short interest during the month of December. As of December 15th, there was short interest totalling 7,300,000 shares, an increase of 25.2% from the November 30th total of 5,830,000 shares. Based on an average trading volume of 71,670,000 shares, the short-interest ratio is presently 0.1 days. Approximately 9.4% of the shares of the company are sold short.

Insider Transactions at CERo Therapeutics

In other CERo Therapeutics news, major shareholder Bioventures Opportunities G. Yk sold 2,998,908 shares of CERo Therapeutics stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $0.06, for a total value of $179,934.48. Following the transaction, the insider now directly owns 13,005,169 shares in the company, valued at approximately $780,310.14. This trade represents a 18.74 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last ninety days, insiders have sold 9,680,126 shares of company stock worth $854,423. Insiders own 18.00% of the company’s stock.

CERo Therapeutics Stock Up 1.9 %

NASDAQ:CERO opened at $0.07 on Tuesday. CERo Therapeutics has a fifty-two week low of $0.05 and a fifty-two week high of $12.80. The firm’s fifty day simple moving average is $0.12 and its 200-day simple moving average is $0.15.

About CERo Therapeutics

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.